PNT insider filings
POINT Biopharma Global Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-12-27. Screen PNT transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for PNT between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — POINT Biopharma Global Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-12-27 | 4 | GOODMAN JONATHAN R. — Director | Code (U): 41,872 · Disposition to issuer (D): 35,872 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative) | EDGAR |
| 2023-12-27 | 4 | KELLY JUSTYNA — Chief Operating Officer | Disposition to issuer (D): 26,904 (derivative) · Disposition to issuer (D): 4,932 (derivative) · Disposition to issuer (D): 70,000 (derivative) · Disposition to issuer (D): 77,958 (derivative) · Disposition to issuer (D): 98,358 (derivative) | EDGAR |
| 2023-12-27 | 4 | MCCANN JOE A. — Chief Executive Officer, Director | Code (U): 2,160 · Code (U): 3,494,153 · Disposition to issuer (D): 381,795 (derivative) · Disposition to issuer (D): 692,643 (derivative) | EDGAR |
| 2023-12-27 | 4 | JENSEN JESSICA D. — EVP Clinical Development | Disposition to issuer (D): 125,553 (derivative) · Disposition to issuer (D): 461,250 (derivative) · Disposition to issuer (D): 213,301 (derivative) · Disposition to issuer (D): 13,766 (derivative) · Disposition to issuer (D): 136,055 (derivative) | EDGAR |
| 2023-12-27 | 4 | FLESHNER NEIL E. — Chief Medical Officer, Director | Code (U): 2,773,045 · Code (U): 233,171 · Code (U): 358 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 60,234 (derivative) · Disposition to issuer (D): 84,257 (derivative) | EDGAR |
| 2023-12-27 | 4 | HOGUE GERALD L. — Director | Code (U): 21,596 · Disposition to issuer (D): 17,936 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative) | EDGAR |
| 2023-12-27 | 4 | DEMERS WILLIAM L. — Chief Financial Officer | Disposition to issuer (D): 179,362 (derivative) · Disposition to issuer (D): 16,767 (derivative) · Disposition to issuer (D): 105,360 (derivative) · Disposition to issuer (D): 131,355 (derivative) | EDGAR |
| 2023-12-27 | 4 | MARGOLIN YAEL — Director | Disposition to issuer (D): 1,710 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative) | EDGAR |
| 2023-12-27 | 4 | Malik Rajesh — Director | Code (U): 3,700 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative) | EDGAR |
| 2023-12-27 | 4 | Lubner David Charles — Director | Code (U): 35,400 · Disposition to issuer (D): 3,600 · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 25,614 (derivative) · Disposition to issuer (D): 44,749 (derivative) | EDGAR |
| 2023-12-27 | 4 | SILBER ALLAN C — Executive Chairman, Director | Code (U): 4,268,605 · Code (U): 313,884 · Code (U): 38,087 · Code (U): 4,035,655 · Code (U): 71,744 · Disposition to issuer (D): 6,787 (derivative) · +2 more | EDGAR |
| 2023-12-20 | 4 | BVF PARTNERS L P/IL BIOTECHNOLOGY VALUE FUND L P BVF I GP LLC BIOTECHNOLOGY VALUE FUND II LP BVF II GP LLC Biotechnology Value Trading Fund OS LP BVF Partners OS Ltd. BVF GP HOLDINGS LLC BVF INC/IL LAMPERT MARK N | Sale (S): 8,974,245 @ $12.45 · Sale (S): 7,290,667 @ $12.45 · Sale (S): 896,366 @ $12.45 | EDGAR |
| 2023-11-07 | 4 | MCCANN JOE A. — Chief Executive Officer, Director | Gift (G): 120,000 @ $0 | EDGAR |
| 2023-11-07 | 4 | SILBER ALLAN C — Executive Chairman, Director | Gift (G): 500,000 @ $0 | EDGAR |
| 2023-11-02 | 4 | FLESHNER NEIL E. — Chief Medical Officer, Director | Gift (G): 250,000 @ $0 | EDGAR |
| 2023-06-14 | 4 | Martell Bridget A — Director | Grant/award (A): 80,503 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | HOGUE GERALD L. — Director | Grant/award (A): 44,749 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | GOODMAN JONATHAN R. — Director | Grant/award (A): 44,749 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | MARGOLIN YAEL — Director | Grant/award (A): 44,749 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Malik Rajesh — Director | Grant/award (A): 44,749 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Lubner David Charles — Director | Grant/award (A): 44,749 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | MCCANN JOE A. — Chief Executive Officer, Director | Grant/award (A): 692,643 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | KELLY JUSTYNA — Chief Operating Officer | Grant/award (A): 98,358 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | JENSEN JESSICA D. — EVP Clinical Development | Grant/award (A): 136,055 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | FLESHNER NEIL E. — Chief Medical Officer, Director | Grant/award (A): 84,257 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | DEMERS WILLIAM L. — Chief Financial Officer | Grant/award (A): 131,355 (derivative) @ $0 | EDGAR |
| 2023-03-30 | 4 | SILBER ALLAN C — Executive Chairman, Director, 10% owner | Grant/award (A): 537,322 (derivative) @ $0 | EDGAR |
| 2023-03-23 | 4 | HOGUE GERALD L. — Director | Option exercise (M): 17,936 @ $6.97 · Option exercise (M): 17,936 (derivative) @ $0 | EDGAR |
| 2022-11-30 | 4 | MCCANN JOE A. — Chief Executive Officer, Director | Purchase (P): 2,160 @ $6.64 | EDGAR |
| 2022-11-28 | 4 | HOGUE GERALD L. — Director | Purchase (P): 3,660 @ $6.82 | EDGAR |
| 2022-11-28 | 4 | Malik Rajesh — Director | Purchase (P): 3,700 @ $6.66 | EDGAR |
| 2022-11-28 | 4 | Lubner David Charles — Director | Purchase (P): 3,600 @ $6.85 | EDGAR |
| 2022-11-23 | 4 | MARGOLIN YAEL — Director | Purchase (P): 1,710 @ $6.56 | EDGAR |
| 2022-11-21 | 4 | GOODMAN JONATHAN R. — Director | Purchase (P): 6,000 @ $6.33 | EDGAR |
| 2022-11-21 | 4 | SILBER ALLAN C — Executive Chairman, Director, 10% owner | Purchase (P): 27,603 @ $6 · Purchase (P): 22,397 @ $6.50 | EDGAR |
| 2022-06-06 | 4 | GOODMAN JONATHAN R. — Director | Grant/award (A): 25,614 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | HOGUE GERALD L. — Director | Grant/award (A): 25,614 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | MARGOLIN YAEL — Director | Grant/award (A): 25,614 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Malik Rajesh — Director | Grant/award (A): 25,614 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Lubner David Charles — Director | Grant/award (A): 25,614 (derivative) @ $0 | EDGAR |
| 2022-05-26 | 4 | FLESHNER NEIL E. — Chief Medical Officer, Director | Sale (S): 564,204 @ $7.51 | EDGAR |
| 2022-04-05 | 4 | JENSEN JESSICA D. — EVP Clinical Development | Grant/award (A): 13,766 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | JENSEN JESSICA D. — EVP Clinical Development | Grant/award (A): 213,301 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | KELLY JUSTYNA — Chief Operating Officer | Grant/award (A): 77,958 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | DEMERS WILLIAM L. — Chief Financial Officer | Grant/award (A): 105,360 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | FLESHNER NEIL E. — Chief Medical Officer, Director | Grant/award (A): 60,234 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | MCCANN JOE A. — Chief Executive Officer, Director | Grant/award (A): 381,795 (derivative) @ $0 | EDGAR |
| 2022-03-31 | 4 | SILBER ALLAN C — Executive Chairman, Director, 10% owner | Grant/award (A): 332,476 (derivative) @ $0 | EDGAR |
| 2022-02-08 | 4/A | GOODMAN JONATHAN R. — Director | Grant/award (A): 35,872 | EDGAR |
| 2021-12-10 | 4 | KELLY JUSTYNA — Chief Operating Officer | Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — POINT Biopharma Global Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-12-27 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-10-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-03 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-02-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-09-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-09-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PNT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs